There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 2 | 543.7 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 1.06%, in the last year to ₹4,215.43 Cr. Its sector's average revenue growth for the last fiscal year was 9.55%.Annual Net Profit,rose 37.34% in the last year to ₹251.18 Cr. Its sector's average net profit growth for the last fiscal year was 29.31%.Price to Earning Ratio,is 34.74, lower than its sector PE ratio of 38.65.Jubilant Ingrevia Limited is a globally integrated Life Sciences and Specialty Chemicals company serving pharmaceutical, nutrition, agrochemical, consumer and industrial customers with a portfolio of over 130 products and customised solutions that meet global quality standards. It is among the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride and Vitamin B3, and has a fast-growing Custom Development and Manufacturing (CDMO) business addressing pharma, agrochemicals and semiconductor sectors. The company serves customers in the US, EU, Japan, the Middle East, South East Asia and India from multiple plants across five manufacturing facilities in India, supported by three R&D centres employing about 150 scientists and a workforce of over 2,300 employees. It was recognised by the World Economic Forum’s Global Lighthouse Network in 2024 for deploying Fourth Industrial Revolution technologies. The company has seven subsidiaries.
Key milestones include: foundation as VAM Organics focused on VAM, acetic acid and acetic anhydride (1978–1990); expansion into Pyridine chemistry and acetyls (1990–2011); forward integration into pyridine derivatives and launch of the Nutrition business (2011–2023); and transformation into a speciality leader with expansion in pyridine derivatives, foray into diketene derivatives, and focus on CDMO and high-value nutrition from 2023 onwards.
– Segment mix (share of turnover):
– Specialty Chemicals: 43.52 Per cent
– Nutrition & Health Solutions: 17.89 Per cent
– Chemical Intermediates: 38.59 Per cent
– Domestic vs international:
– Exports contributed 45.75 Per cent of turnover in FY 2025.
– Shyam S. Bhartia – Chairman
– Hari S. Bhartia – Co-Chairman and Whole-time Director
– Deepak Jain – CEO and Managing Director
– Varun Gupta – President and Chief Financial Officer
– Deepanjali Gulati – Company Secretary
– Recognition: The World Economic Forum named Jubilant Ingrevia’s Bharuch facility to the Global Lighthouse Network in 2024, marking the first Indian chemical manufacturer in that cohort.
– Digital initiatives: The company deployed an AI-driven retrosynthesis platform to accelerate R&D and an integrated SmartProject PMIS to enhance project execution with real-time collaboration and analytics.
– Capacity and launches: A food- and cosmetic-grade niacinamide and niacin facility was commissioned at Bharuch during the year.
– CDMO traction: Two agro-CDMO contracts were signed; pharmaceutical CDMO work progressed across 15 molecules and semiconductor CDMO across 8–10 molecules.
– Market momentum: Export share rose to 46 Per cent, with sales in the US up 52 Per cent year-on-year and Europe & Japan up 16 Per cent.
– Energy transition: The company is targeting to source 35 Per cent of overall power through a renewables contract (O2), and has invested in the related platform.
It manufactures and supplies life sciences and specialty chemical ingredients across pharma, nutrition, agrochemicals, consumer and industrial end-markets, with capabilities spanning CDMO services. The company is a global leader in pyridine derivatives and acetic anhydride, among others.
It serves customers across the US, EU, Japan, the Middle East, South East Asia and India, operating multiple plants within five manufacturing facilities in India. Three R&D centres with around 150 scientists support innovation.
The company operates three segments—Specialty Chemicals, Nutrition & Health Solutions and Chemical Intermediates—contributing 43.52 Per cent, 17.89 Per cent and 38.59 Per cent of turnover, respectively. Exports accounted for 45.75 Per cent of turnover in FY 2025.
